Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
gemcitabine + lobaplatin
- Development stage
- Unknown
- Lead developer
- Eli Lilly
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
A combination chemotherapy regimen consisting of gemcitabine and lobaplatin. Gemcitabine is a pyrimidine nucleoside antimetabolic drug that primarily interferes with DNA synthesis in tumor cells, specifically during the S phase of the cell cycle. Lobaplatin is a platinum-based chemotherapeutic agent. When combined with gemcitabine, this regimen has been shown to reduce levels of vascular endothelial growth factor (VEGF) and matrix metalloproteinase-9 (MMP-9) in patients' serum, which may contribute to its therapeutic efficacy in locally advanced cervical cancer.
02
Targets
RNR (Ribonucleotide reductase)DNADNA polymerase family
Beyond the preview
Go deeper on gemcitabine + lobaplatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on gemcitabine + lobaplatin.